VIRX241220C5000
- 0.00
- 0.000.00%
Viracta Therapeutics Newsroom
Express News | Viracta Therapeutics Inc - Receives Notice of Non-Compliance From Nasdaq
Viracta Therapeutics Is Maintained at Outperform by RBC Capital
RBC Cuts Price Target on Viracta Therapeutics to $2 From $4, Keeps Outperform, Speculative Risk
Viracta Therapeutics | 10-Q: Q3 2024 Earnings Report
Viracta Therapeutics | 8-K: Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Viracta Therapeutics Reports Q3 EPS (27c) Vs (33c) Last Year
Express News | Viracta Therapeutics: Cash Position Sufficient to Fund Operations Late Into Q1 2025
Press Release: Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Express News | Viracta Therapeutics Q3 Net Income USD -10.6 Million
Express News | Viracta Therapeutics Q3 EPS USD -0.27
Viracta Therapeutics Reports 42% Reduction in Force, Strategic Reprioritization
Viracta Therapeutics Restructures to Focus on Nana-val Program
Viracta Therapeutics: Expect to Recognize About $700,000 in Total Expenses for Severance and Related Benefits >VIRX
Viracta Therapeutics: Implementing 42% Reduction in Force and Resizing Bd of Directors to Six Seats From Ten >VIRX
Express News | Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-Val Development Program in Patients With Relapsed or Refractory Ebv-Positive Peripheral T-Cell Lymphoma
Trending Stocks Today | Healthcare Triangle Shoots up 121.07% Pre-Market
Q3 Pharma and Biotech Layoffs in Charts: More Than 1000 Each in July and August
12 Health Care Stocks Moving In Friday's After-Market Session
Express News | Viracta Therapeutics Shares Are Trading Lower After Leerink Partners Downgraded the Stock From Outperform to Market Perform and Lowered Its Price Target From $5 to $3
Express News | Viracta Therapeutics Inc : Leerink Partners Cuts to Market Perform From Outperform; Cuts Target Price to $3 From $5